Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Cellyan Biotechnology Co., Ltd

CIK 2007702Updated Nov 17, 2026

Name history
Hong Kong Pharma Digital Technology Holdings Ltd · through Dec 17, 2025

HKPD price & chart

Provider market data

Loading TradingView…

NASDAQ:HKPD on TradingView ↗

TradingView · Data may be delayed

About the company

Cellyan Biotechnology is a Cayman Islands exempted company, and each of the HK Subsidiaries is a Hong Kong company. Currently, there are no restrictions or limitations under the laws of Hong Kong on (i) foreign exchange or the conversion of HK dollars into foreign currencies and the remittance of currencies out of Hong Kong, (ii) the transfer of cash or other assets between Cellyan Biotechnology and any of the HK Subsidiaries, across borders, or to U.S. investors, or (iii) the distribution of earnings from the HK Subsidiaries to Cellyan Biotechnology or U.S. investors. However, if certain PRC laws and regulations, including existing laws and regulations and those enacted or promulgated in the future, were to become applicable to our HK Subsidiaries, to the extent our cash or assets are in Hong Kong or with a Hong Kong entity, such funds or assets may not be available to fund operations or for other use outside of Hong Kong due to interventions in or the imposition of restrictions and limitations on the HK Subsidiaries’ ability to transfer funds or assets by the PRC government. We cannot assure you that the PRC government will not intervene or impose restrictions on the HK Subsidiar…

F-1 · 2026-03-27 · 0001213900-26-035450

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue20,313,818USD · FY 2025
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Net income-27,056USD · FY 2025
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Assets—USD · FY 2025
Cash— · FY 2025
Operating income-2,284,587USD · FY 2025
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Diluted EPS-0USD per share · FY 2025
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemFY 2025
Cash flows from operating activities:
Profit or LossUSD-27,056
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Additional Financial Items
AdjustmentsForFinanceCostsUSD43,145
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD294,831
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

InterestPaidClassifiedAsOperatingActivitiesUSD97,667
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD1,002,588
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD769,922
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

ProceedsFromIssuingSharesUSD4,000,000
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD85,072
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD237,826
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025
Cost of Goods and Services Sold—
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Selling, General and Administrative ExpenseUSD2,215,859
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Total RevenueUSD20,313,818
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Additional Financial Items
ApplicableTaxRatenumber0.17
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

AverageEffectiveTaxRatenumber1.75
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

BasicEarningsLossPerShareUSD per share-0
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

CurrentTaxExpenseIncomeUSD63,168
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

DepreciationAndAmortisationExpenseUSD66,091
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

DilutedEarningsLossPerShareUSD per share-0
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

FinanceCostsUSD97,667
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

FinanceIncomeUSD1,741
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

GrossProfitUSD2,415,159
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

IncomeTaxExpenseContinuingOperationsUSD63,168
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

InterestExpenseOnLeaseLiabilitiesUSD34,775
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

OtherIncomeUSD1,466
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

ProfitLossAttributableToOwnersOfParentUSD-27,056
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

ProfitLossBeforeTaxUSD36,112
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

ProfitLossFromOperatingActivitiesUSD-2,284,587
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

TaxRateEffectOfForeignTaxRatesnumber1.87
Source

20-F · 2025-08-14 · 0001213900-25-076725

2024-04-01 to 2025-03-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-296754

F-3 · 2026-06-12 · 0001213900-26-068308

Terms from the governing filing for this registration; not a claim that the offering is open today.

Registration 333-294685

F-1 · 2026-03-27 · 0001213900-26-035450

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ea031239701ex99-1.htm · 6-K · 2026-11-16

Exhibit 99.1 CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2…

6-K · 2026-11-16 · 0001213900-26-120090

Read attachment ↗
ea030894801ex99-1.htm · 6-K · 2026-10-21

Exhibit 99.1 Cellyan Biotechnology Announces a 1-for-20 Reverse Stock Split HONG KONG, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, announced that it expects to implement a 1-for-20 reverse stock split, or consolidation of its issued and unissued Class A ordinary shares and Class B ordinary shares, par value $0.001 per sha…

6-K · 2026-10-21 · 0001213900-26-111190

Read attachment ↗
ea030497601ex99-1.htm · 6-K · 2026-09-10

Exhibit 99.1 CELLYAN BIOTECHNOLOGY CO., LTD NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON September 20, 2026 Notice is hereby given that Cellyan Biotechnology Co., Ltd, a Cayman Islands exempted company (the “Company”), will hold its Extraordinary General Meeting of shareholders at 10 P.M., Hong Kong time, on September 21, 2026 (10 A.M., Eastern time, on September 21, 2026) (the “Extraordinary Meeting”) at 11th Floor, Xinghe Development Center, Fuhua 3rd Road, Futian D…

6-K · 2026-09-10 · 0001213900-26-098532

Read attachment ↗
ea030497601ex99-2.htm · 6-K · 2026-09-10

Exhibit 99.2 CELLYAN BIOTECHNOLOGY CO., LTD ROOM B1, 5/F. WELL TOWN IND. BUILDING 13 KO FAI ROAD, YAU TONG, KOWLOON HONG KONG VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an el…

6-K · 2026-09-10 · 0001213900-26-098532

Read attachment ↗
ea029805301ex4-1.htm · S-8 · 2026-08-13

Exhibit 4.1 CELLYAN BIOTECHNOLOGY CO., LTD (the “Company”) (Registration Number 402778) Class A Ordinary Share(s) Number ────────── Incorporated under the laws of the Cayman Islands Share capital is US$1,000,000 divided into 1,000,000,000 Ordinary Shares of par value of US$0.001 each, comprising: (i) 940,000,000 Class A Ordinary Shares of par value of US$0.001 and (ii) 60,000,000 Class B Ordinary Shares of par value of US$0.001 each. THIS IS TO CERTIFY THAT is the registered h…

S-8 · 2026-08-13 · 0001213900-26-089057

Read attachment ↗
ea029978901ex4-3.htm · 20-F · 2026-08-07

Exhibit 4.3 Overseas Central Warehouse Service Agreement This Agreement is entered into by and between the following parties: 1. Hangzhou Cainiao Supply Chain Management Co., Ltd., a company established under the laws of the People’s Republic of China, with its registered address at Room V424, No. 501 Fengxin Road, Yuhang Street, Yuhang District, Hangzhou City, Zhejiang Province, China (hereinafter referred to as “Party A” or “Cainiao”), and 2. Joint Cross Border Logistics Company Limited, a…

20-F · 2026-08-07 · 0001213900-26-086725

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.